Navigation Links
Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
Date:5/26/2010

BOSTON, May 26 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company generated $104,774 in revenues for the first quarter ended March 31, 2010 as compared to $95,227 in the first quarter 2009, which represents a 10 percent increase. As of March 31, 2010, Solos reported $2,276,462 in total assets. The Company has posted its financial results for the first quarter ended March 31, 2010 on Pink Sheets OTC Markets website (http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=sndy).

Solos recently announced the appointment of Fred Schiemann to its board of directors and Chief Financial Officer. Mr. Schiemann brings a strong administrative background in the small-cap company sector as well as expertise  in taxation, auditing and public securities work. During his years of practice,  Mr. Schiemann has been involved with many public registrations and structuring of mergers and acquisitions. His current practice includes an emphasis on administration and consulting to small and micro-cap public companies.

"We are pleased with the results of our first quarter," stated Bob Segersten, President of Solos Endoscopy, Inc. "We posted double-digit revenue growth and we feel great about our position as we continue to progress towards market  expansion abroad."

Throughout the remainder of 2010, the Company will continue its new product development for the MammoView® product line as well as market expansion through its efforts to meet the requirements of the ISO 13485 standard and ultimately  obtain the CE Mark and the permission to sell medical devices in the European Union and Canada.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional  information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the  meaning of Section 27A of the Securities Act of 1933 and Section 27E of the  Securities Act of 1934. Statements contained in this release that are not  historical facts may be deemed to be forward-looking statements. Investors are  cautioned that forward-looking statements are inherently uncertain. Actual  performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for  anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc. Appoints Experienced CFO To Financial Leadership Amidst Growth
2. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
3. Solos Endoscopy, Inc. Set To Develop European Union Conforming CE Mark Technical File
4. Solos Endoscopy, Inc. Set To Develop New Polymer Dilator For MammoView(TM) System
5. Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
6. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in February Issue of General Surgery News
7. Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010
8. Solos Endoscopy, Inc. Outlines Marketing Strategy for 2010 Campaign
9. Solos Endoscopy, Inc. Makes Significant Design Improvement To Its MammoView(TM) Ductoscope
10. Solos Endoscopy, Inc. Reports Sales Increase for October 2009 and November 2009 as Compared to Same Two Months in 2008
11. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in November Issue of Healthcare Purchasing News Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
(Date:4/19/2017)... research provides evidence that an old drug may provide relief ... today that will be presented at the American Academy ... , April 22 to 28, 2017. ... oral drug levodopa has long been considered the gold standard, ... progresses, the effects of the medication can partially wear off ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy ... the preferred physical therapy provider for Derby City CrossFit, effective immediately. , In ... as quickly and effectively as possible, ProRehab’s sports physical therapists will work with ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... Liberty attempts to compare student test score performance for the 2015-16 school year ... the state’s voucher programs. Though it highlights important patterns in student test score ...
(Date:4/25/2017)... ... 2017 , ... As pharmaceutical companies are held to increasingly ... innovation in drug formulation and manufacturing. CoreRx offers its clients more than ... support of their development and manufacturing goals. , The company was created ...
(Date:4/25/2017)... ... , ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care ... on preventative care with all my patients to alleviate possible future issues. I am pleased ... contact my office and my trained staff will assist you in any way possible.” , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):